Tilray Brands, Inc.

WBAG:TLRY Stock Report

Market Cap: €1.2b

Tilray Brands Valuation

Is TLRY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TLRY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TLRY (€1.31) is trading above our estimate of fair value (€0.75)

Significantly Below Fair Value: TLRY is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TLRY?

Key metric: As TLRY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TLRY. This is calculated by dividing TLRY's market cap by their current revenue.
What is TLRY's PS Ratio?
PS Ratio1.5x
SalesUS$812.04m
Market CapUS$1.21b

Price to Sales Ratio vs Peers

How does TLRY's PS Ratio compare to its peers?

The above table shows the PS ratio for TLRY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.4x
MARI Marinomed Biotech
2.3xn/a€15.4m
719 Shandong Xinhua Pharmaceutical
0.4xn/aHK$9.3b
688321 Shenzhen Chipscreen Biosciences
13.1x28.6%CN¥8.6b
600557 Jiangsu Kanion PharmaceuticalLtd
1.8x16.0%CN¥8.1b
TLRY Tilray Brands
1.5x7.9%€1.2b

Price-To-Sales vs Peers: TLRY is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does TLRY's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x7.4%
TLRY Tilray Brands
 1.5x7.9%US$1.21b
TLRY 1.5xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x15.8%
TLRY Tilray Brands
 1.5x72.0%US$1.21b
No more companies

Price-To-Sales vs Industry: TLRY is good value based on its Price-To-Sales Ratio (1.5x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is TLRY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TLRY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TLRY's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TLRY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.31
€2.09
+59.2%
26.6%€3.80€1.66n/a13
Nov ’25€1.54
€2.02
+31.8%
26.2%€3.66€1.60n/a13
Oct ’25€1.55
€2.09
+34.9%
23.8%€3.61€1.72n/a14
Sep ’25€1.52
€2.20
+44.3%
24.7%€3.70€1.76n/a14
Aug ’25€1.91
€2.20
+15.4%
24.7%€3.70€1.76n/a14
Jul ’25€1.58
€2.22
+40.3%
22.8%€3.74€1.78n/a17
Jun ’25€1.66
€2.21
+33.0%
22.8%€3.73€1.77n/a17
May ’25€1.66
€2.21
+33.3%
22.8%€3.73€1.77n/a17
Apr ’25€2.25
€2.41
+6.7%
26.7%€3.96€1.86n/a16
Mar ’25€1.62
€2.41
+48.7%
26.7%€3.96€1.86n/a16
Feb ’25€1.74
€2.36
+36.1%
27.4%€3.93€1.76n/a17
Jan ’25€2.20
€2.43
+10.3%
24.6%€3.89€1.74n/a17
Dec ’24€1.68
€2.50
+48.8%
23.4%€3.88€1.74n/a17
Nov ’24€1.67
€2.58
+55.1%
24.1%€4.01€1.79€1.5416
Oct ’24€2.22
€2.78
+25.2%
33.2%€5.20€1.80€1.5516
Sep ’24€2.68
€2.57
-4.1%
35.8%€5.02€1.73€1.5216
Aug ’24€2.15
€2.58
+20.2%
41.2%€5.92€1.73€1.9116
Jul ’24€1.41
€3.02
+114.8%
37.5%€5.93€1.82€1.5816
Jun ’24€1.62
€3.20
+98.4%
32.4%€5.92€2.05€1.6615
May ’24€2.16
€3.20
+48.1%
32.4%€5.92€2.05€1.6615
Apr ’24€2.38
€4.10
+72.4%
41.7%€8.48€2.64€2.2516
Mar ’24€2.61
€4.10
+57.2%
41.7%€8.48€2.64€1.6216
Feb ’24€2.91
€4.13
+42.1%
43.1%€8.19€2.55€1.7415
Jan ’24€2.52
€4.76
+88.7%
52.2%€11.99€2.00€2.2018
Dec ’23n/a
€4.76
0%
52.2%€11.99€2.00€1.6818
Nov ’23n/a
€4.92
0%
54.0%€12.15€2.02€1.6718

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM

€8.40

7D

-0.5%

1Y

0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.30

7D

4.2%

1Y

85.6%

Bayer

€19.5b

Operates as a life science company worldwide.

BAYN

€19.77

7D

-3.7%

1Y

-39.4%